HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms

Journal of Lipid Research

Volumn 55, Issue 8, 2014, Pages 1678-1692

  Emert, Benjamin ^a   Hasin Brumshtein, Yehudit ^a   Springstead, James R ^c   Vakili, Ladan ^a   Berliner, Judith A ^a,b   Lusis, Aldons J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

High density lipoprotein; Inflammatory signaling; Minimally modified low density lipoprotein; Platelet activating factor acetylhydrolase; Scavenger receptor class B type I

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 PALMITOYL 2 ARACHIDONYL SN GLYCERO 3 PHOSPHOCHOLINE; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PHOSPHORYLCHOLINE; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; PHOSPHOLIPID;

ANGIOGENESIS; AORTA; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; LIPID HYDROLYSIS; LIPID OXIDATION; MOLECULAR DYNAMICS; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; TRANSCRIPTION REGULATION; CELL CULTURE; DRUG EFFECTS; METABOLISM;

CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS, HDL; PHOSPHOLIPIDS;

EID: 84905056464     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M047738     Document Type: Article

References (57)

1. Kannel, W. B., T. R. Dawber, G. D. Frideman, W. E. Glennon, and P. M. McNamara. 1964. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease: the Framingham Study. Ann. Intern. Med. 61: 888-899.
2. Kannel, W. B., T. R. Dawber, A. Kagan, N. Revotskie, and J. Stokes III. 1961. Factors of risk in the development of coronary heart disease - six-year follow-up experience: the Framingham Study. Ann. Intern. Med. 55: 33-50.
3. Lusis, A. J. 2000. Atherosclerosis. Nature. 407: 233-241.
4. Vaya J. 2013. The association between biomarkers in the blood and carotid plaque composition-focusing on oxidized lipids, oxysterols and plaque status. Biochem Pharmacol. 86: 15-18.
5. Berliner, J. A., and A. D. Watson. 2005. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353: 9-11. (Pubitemid 41007802)
6. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Hörkkö, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607. (Pubitemid 27224791)
7. Berliner, J. A., N. Leitinger, and S. Tsimikas. 2009. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50 (Suppl.): S207-S212.
8. Romanoski, C. E., N. Che, F. Yin, N. Mai, D. Pouldar, M. Civelek, C. Pan, S. Lee, L. Vakili, W-P. Yang, et al. 2011. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. Circ. Res. 109: e27-e41.
9. Lee, S., K. G. Birukov, C. E. Romanoski, J. R. Springstead, A. J. Lusis, and J. A. Berliner. 2012. Role of phospholipid oxidation products in atherosclerosis. Circ. Res. 111: 778-799.
10. Faria-Neto, J. R., K-Y. Chyu, X. Li, P. C. Dimayuga, C. Ferreira, J. Yano, B. Cercek, and P. K. Shah. 2006. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis. 189: 83-90. (Pubitemid 44468069)
11. Caligiuri, G., J. Khallou-Laschet, M. Vandaele, A-T. Gaston, S. Delignat, C. Mandet, H. V. Kohler, S. V. Kaveri, and A. Nicoletti. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50: 540-546. (Pubitemid 47126777)
12. Binder, C. J., S. Hörkkö, A. Dewan, M-K. Chang, E. P. Kieu, C. S. Goodyear, P. X. Shaw, W. Palinski, J. L. Witztum, and G. J. Silverman. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743. (Pubitemid 36749223)
13. Tsimikas, S., A. Miyanohara, K. Hartvigsen, E. Merki, P. X. Shaw, M-Y. Chou, J. Pattison, M. Torzewski, J. Sollors, T. Friedmann, et al. 2011. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58: 1715-1727.
14. Lichtman, A. H., C. J. Binder, S. Tsimikas, and J. L. Witztum. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Invest. 123: 27-36.
15. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316. (Pubitemid 19267219)
16. Riwanto, M., and U. Landmesser. 2013. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res. 54: 3227-3243.
17. Mineo, C., and P. W. Shaul. 2013. Regulation of signal transduction by HDL. J. Lipid Res. 54: 2315-2324.
18. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364. (Pubitemid 43948059)
19. Rye, K-A., and P. J. Barter. 2014. Cardioprotective functions of HDLs. J. Lipid Res. 55: 168-179.
20. Terasaka, N., M. Westerterp, J. Koetsveld, C. Fernández-Hernando, L. Yvan-Charvet, N. Wang, W. C. Sessa, and A. R. Tall. 2010. ATPbinding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler. Thromb. Vasc. Biol. 30: 2219-2225.
21. Rämet, M. E., M. Rämet, Q. Lu, M. Nickerson, M. J. Savolainen, A. Malzone, and R. H. Karas. 2003. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41: 2288-2297. (Pubitemid 36724281)
22. Mineo, C., and P. W. Shaul. 2003. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc. Med. 13: 226-231. (Pubitemid 36960169)
23. Gharavi, N. M., P. S. Gargalovic, I. Chang, J. A. Araujo, M. J. Clark, W. L. Szeto, A. D. Watson, A. J. Lusis, and J. A. Berliner. 2007. High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler. Thromb. Vasc. Biol. 27: 1346-1353. (Pubitemid 46809424)
24. Rader, D. J., and A. R. Tall. 2012. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18: 1344-1346.
25. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Hólm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 380: 572-580.
26. AIM-HIGH Investigators, W. E. Boden, J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
27. Rosenson, R. S., H. B. Brewer, B. Ansell, P. Barter, M. J. Chapman, J. W. Heinecke, A. Kontush, A. R. Tall, and N. R. Webb. 2013. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 128: 1256-1267.
28. Zhong, W., J. R. Springstead, R. Al-Mubarak, S. Lee, R. Li, B. Emert, J. A. Berliner, and M. E. Jung. 2013. An epoxyisoprostane is a major regulator of endothelial cell function. J. Med. Chem. 56: 8521-8532.
29. Watson, A. D., M. Navab, S. Y. Hama, A. Sevanian, S. M. Prescott, D. M. Stafforini, T. M. McIntyre, B. N. Du, A. M. Fogelman, and J. A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95: 774-782.
30. Bligh, E. G., and W. J. Dyer. 1959. A rapid method for total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
31. Yeh, M., A. L. Cole, J. Choi, Y. Liu, D. Tulchinsky, J-H. Qiao, M. C. Fishbein, A. N. Dooley, T. Hovnanian, K. Mouilleseaux, et al. 2004. Role for sterol regulatory element-binding protein in activation of endothelial cells by phospholipid oxidation products. Circ. Res. 95: 780-788. (Pubitemid 39390580)
32. Everson, W. V., and E. J. Smart. 2001. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc. Med. 11: 246-250. (Pubitemid 32982916)
33. Uittenbogaard, A., P. W. Shaul, I. S. Yuhanna, A. Blair, and E. J. Smart. 2000. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275: 11278-11283. (Pubitemid 30212775)
34. Romanoski, C. E., S. Lee, M. J. Kim, L. Ingram-Drake, C. L. Plaisier, R. Yordanova, C. Tilford, B. Guan, A. He, P. S. Gargalovic, et al. 2010. Systems genetics analysis of gene-by-environment interactions in human cells. Am. J. Hum. Genet. 86: 399-410.
35. Argraves, K. M., P. J. Gazzolo, E. M. Groh, B. A. Wilkerson, B. S. Matsuura, W. O. Twal, S. M. Hammad, and W. S. Argraves. 2008. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 283: 25074-25081.
36. Wilkerson, B. A., G. D. Grass, S. B. Wing, W. S. Argraves, and K. M. Argraves. 2012. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 287: 44645-44653.
37. Leitinger, N., A. D. Watson, S. Y. Hama, B. Ivandic, J-H. Qiao, J. Huber, K. F. Faull, D. S. Grass, M. Navab, A. M. Fogelman, et al. 1999. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 19: 1291-1298. (Pubitemid 29227650)
38. Subramanian, V. S., J. Goyal, M. Miwa, J. Sugatami, M. Akiyama, M. Liu, and P. V. Subbaiah. 1999. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochim. Biophys. Acta. 1439: 95-109. (Pubitemid 29296867)
39. McIntyre, T. M., S. M. Prescott, and D. M. Stafforini. 2009. The emerging roles of PAF acetylhydrolase. J. Lipid Res. 50 (Suppl.): S255-S259.
40. Van Lenten, B. J., A. C. Wagner, C-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
41. Bowry, V. W., K. K. Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA. 89: 10316-10320.
42. Springstead, J. R., B. G. Gugiu, S. Lee, S. Cha, A. D. Watson, and J. A. Berliner. 2012. Evidence for the importance of OxPAPC interaction with cysteines in regulating endothelial cell function. J. Lipid Res. 53: 1304-1315.
43. Oskolkova, O. V., T. Afonyushkin, B. Preinerstorfer, W. Bicker, E. von Schlieffen, E. Hainzl, S. Demyanets, G. Schabbauer, W. Lindner, A. D. Tselepis, et al. 2010. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J. Immunol. 185: 7706-7712.
44. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523. (Pubitemid 35154710)
45. Podrez, E. A. 2010. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol. 37: 719-725.
46. McGrath, K. C. Y., X. H. Li, R. Puranik, E. C. Liong, J. T. M. Tan, V. M. Dy, B. A. DiBartolo, P. J. Barter, K-A. Rye, and A. K. Heather. 2009. Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 29: 877-882.
47. Augsten, M., H. Hackl, B. Ebner, A. Chemelli, O. Glatter, G. Marsche, U. Lang, G. Desoye, and C. Wadsack. 2011. Fetal HDL/apoE: a novel regulator of gene expression in human placental endothelial cells. Physiol. Genomics. 43: 1255-1262.
48. Tabet, F., K. C. Vickers, L. F. Cuesta Torres, C. B. Wiese, B. M. Shoucri, G. Lambert, C. Catherinet, L. Prado-Lourenco, M. G. Levin, S. Thacker, et al. 2014. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 5: 3292.
49. Kimura, T., H. Tomura, C. Mogi, A. Kuwabara, A. Damirin, T. Ishizuka, A. Sekiguchi, M. Ishiwara, D-S. Im, K. Sato, et al. 2006. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281: 37457-37467. (Pubitemid 46042049)
50. Seetharam, D., C. Mineo, A. K. Gormley, L. L. Gibson, W. Vongpatanasin, K. L. Chambliss, L. D. Hahner, M. L. Cummings, R. L. Kitchens, Y. L. Marcel, et al. 2006. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 98: 63-72. (Pubitemid 43970204)
51. Zhu, W., S. Saddar, D. Seetharam, K. L. Chambliss, C. Longoria, D. L. Silver, I. S. Yuhanna, P. W. Shaul, and C. Mineo. 2008. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ. Res. 102: 480-487. (Pubitemid 351651102)
52. Zhang, Q-H., X-Y. Zu, R-X. Cao, J-H. Liu, Z-C. Mo, Y. Zeng, Y-B. Li, S-L. Xiong, X. Liu, D-F. Liao, et al. 2012. An involvement of SR-B1 mediated PI3K-Akt-eNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacyclin production in endothelial cells. Biochem. Biophys. Res. Commun. 420: 17-23.
53. Yuhanna, I. S., Y. Zhu, B. E. Cox, L. D. Hahner, S. Osborne-Lawrence, P. Lu, Y. L. Marcel, R. G. Anderson, M. E. Mendelsohn, H. H. Hobbs, et al. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7: 853-857. (Pubitemid 32691642)
54. Yancey, P. G., A. E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M. C. Phillips, and G. H. Rothblat. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23: 712-719. (Pubitemid 36566157)
55. Watson, A. D., G. Subbanagounder, D. S. Welsbie, K. F. Faull, M. Navab, M. E. Jung, A. M. Fogelman, J. A. Berliner. 1999. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem. 274: 24787-98.
56. Szapacs, M. E., H. Y. Kim, N. A. Porter, and D. C. Liebler. 2008. Identification of proteins adducted by lipid peroxidation products in plasma and modifications of apolipoprotein A1 with a novel biotinylated phospholipid probe. J. Proteome Res. 7: 4237-4246.
57. Gao, D., B. Willard, and E. A. Podrez. 2014. Analysis of covalent modifications of proteins by oxidized phospholipids using a novel method of peptide enrichment. Anal. Chem. 86: 1254-1262.